Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3921 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Positive phase II for Corcept antipsychotic

The results of the study, which are published in the Journal of Biological Psychiatry, showed that patients who received Corlux were more likely than patients who received placebo

BioCryst gets FDA approval for pivotal anticancer trial

The special protocol assessment (SPA) letter documents the agreement between FDA and BioCryst regarding the trial design’s suitability to support regulatory approval. The multicenter, open-label, nonrandomized, repeat-dose pivotal

Lilly pulls out of licensing deal with Taisho

Taisho, headquartered in Tokyo, granted Lilly exclusive rights for development and commercialization of TS-021 worldwide except for Japan and China under a license agreement executed in July 2005.

Teva wins US approval for generic Effexor

According to Teva, Effexor has annual sales of approximately $152 million. The Israeli company said that it would begin to ship its generic version of the product immediately.